Opendata, web and dolomites

GLIOTRAIN SIGNED

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "GLIOTRAIN" data sheet

The following table provides information about the project.

Coordinator
ROYAL COLLEGE OF SURGEONS IN IRELAND 

Organization address
address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2
website: www.rcsi.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://www.gliotrain.eu/
 Total cost 3˙836˙772 €
 EC max contribution 3˙836˙772 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) coordinator 1˙062˙698.00
2    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 510˙748.00
3    VIB VZW BE (ZWIJNAARDE - GENT) participant 501˙120.00
4    UNIVERSITAET STUTTGART DE (STUTTGART) participant 498˙432.00
5    INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE FR (PARIS) participant 262˙875.00
6    AGILENT TECHNOLOGIES BELGIUM NV BE (DIEGEM) participant 250˙560.00
7    INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA LU (Esch-sur-Alzette) participant 250˙560.00
8    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 250˙560.00
9    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 249˙216.00
10    BMS France FR (Argonay) partner 0.00
11    CarThera FR (Paris) partner 0.00
12    Champions Oncology, Inc. US (Hackensack, NJ) partner 0.00
13    INSILICO BIOTECHNOLOGY AG DE (STUTTGART) partner 0.00
14    International Brain Tumour Alliance UK (London) partner 0.00
15    IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG IE (DUBLIN 11) partner 0.00
16    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) partner 0.00
17    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) partner 0.00
18    MIMETAS BV NL (Leiden) partner 0.00
19    Oncurious NV BE (Leuven) partner 0.00
20    Pepscope BV NL (Utrecht) partner 0.00
21    TEVA PHARMACEUTICALS EUROPE B.V. NL (AMSTERDAM) partner 0.00
22    UNIVERSITE DU LUXEMBOURG LU (ESCH-SUR-ALZETTE) partner 0.00
23    YUMAB GmbH DE (Braunschweig) partner 0.00

Map

 Project objective

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

 Deliverables

List of deliverables.
Dissemination and public engagement Report 1 Documents, reports 2020-01-14 15:07:41
GLIOTRAIN Web presence Websites, patent fillings, videos etc. 2020-01-14 15:09:36
Dissemination and public engagement Report 2 Documents, reports 2020-01-14 15:06:43

Take a look to the deliverables list in detail:  detailed list of GLIOTRAIN deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Annika Hantusch; Kushal K. Das; Ana J. García-Sáez; Thomas Brunner; Markus Rehm
Bax retrotranslocation potentiates Bcl-xL’s antiapoptotic activity and is essential for switch-like transitions between MOMP competency and resistance
published pages: 430, ISSN: 2041-4889, DOI: 10.1038/s41419-018-0464-6
Cell Death & Disease 9 (4) 2019-10-15
2019 Ian S. Miller, Liam P. Shiels, Emer Conroy, Kate Connor, Patrick Dicker, William M. Gallagher, Norma O’ Donovan, Robert S. Kerbel, John Crown, Annette T. Byrne
Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents
published pages: 9204, ISSN: 2045-2322, DOI: 10.1038/s41598-019-45444-0
Scientific Reports 9/1 2019-10-15
2018 Frank A. Lincoln, Dirke Imig, Chiara Boccellato, Viktorija Juric, Janis Noonan, Roland E. Kontermann, Frank Allgöwer, Brona M. Murphy, Markus Rehm
Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
published pages: 1112, ISSN: 2041-4889, DOI: 10.1038/s41419-018-1160-2
Cell Death & Disease 9/11 2019-10-15
2019 Bo Lou, Kate Connor, Kieron Sweeney, Ian S. Miller, Alice O’Farrell, Eduardo Ruiz-Hernandez, David M. Murray, Garry P. Duffy, Alan Wolfe, Enrico Mastrobattista, Annette T. Byrne, Wim E. Hennink
RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells
published pages: 679-693, ISSN: 2190-393X, DOI: 10.1007/s13346-019-00637-y
Drug Delivery and Translational Research 9/3 2019-10-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOTRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EuroPLEx (2019)

European network for Particle physics, Lattice field theory and Extreme computing

Read More  

UHMob (2019)

Ultra-high Charge Carrier Mobility to Elucidate Transport Mechanisms in Molecular Semiconductors

Read More  

CO2PERATE (2020)

Cooperation towards a sustainable chemical industry

Read More